Does cancer type and adjuvant analgesic prescribing influence opioid dose?-a retrospective cross-sectional study.

Wong, AK; Hawke, J; Eastman, P; Buizen, L; Le, B

Does cancer type and adjuvant analgesic prescribing influence opioid dose?-a retrospective cross-sectional study.

Wong, AK Hawke, J Eastman, P Buizen, L Le, B

Permalink

Publisher:: AME Publishing Company
Publication Type:: Journal Article
Citation:: Ann Palliat Med, 2023, 12, (4), pp. 783-790
Issue Date:: 2023-07

Closed Access

	Filename	Description	Size
	112569-PB7-4781-R2.pdf	Published version	206.06 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Wong, AK
dc.contributor.author	Hawke, J
dc.contributor.author	Eastman, P
dc.contributor.author	Buizen, L
dc.contributor.author	Le, B https://orcid.org/0000-0002-0830-4864
dc.date.accessioned	2023-11-07T04:28:50Z
dc.date.available	2023-03-14
dc.date.available	2023-11-07T04:28:50Z
dc.date.issued	2023-07
dc.identifier.citation	Ann Palliat Med, 2023, 12, (4), pp. 783-790
dc.identifier.issn	2224-5820
dc.identifier.issn	2224-5839
dc.identifier.uri	http://hdl.handle.net/10453/173196
dc.description.abstract	Opioids are the backbone of cancer pain management. Minimal evidence exists examining the relationship between cancer type and opioid dose. Similarly, the use of adjuvant analgesics and its impact within an inpatient cancer setting is understudied. This study examined the influence of cancer type upon opioid dose, measured by oral morphine equivalent daily dose (oMEDD). The effect of adjuvant analgesics on patient oMEDD was also examined. This retrospective cross-sectional study examined records of 520 patients admitted to Royal Melbourne Hospital or Peter MacCallum Cancer Centre between 2016 and 2018 with advanced cancer. Number and dose of both opioid and adjuvant analgesics were collected along with demographic and cancer data. Comparisons of median oMEDD by cancer type [analysis of variance (ANOVA), non-parametric t-tests] and adjuvant analgesics (Kruskal-Wallis test) were performed. There were no statistically significant differences in oMEDD between the 12 cancer types (P=0.83; n=215). Patients co-prescribed pregabalin (n=102) and paracetamol (n=73) as adjuvant analgesics were on significantly higher daily oMEDD [60 mg (P=0.015), 90 mg (P<0.001), respectively]. Opioid dose did not differ significantly between cancer types. The observed use of adjuvant analgesics coincided with significantly higher oMEDD prescription which may relate to complex pain seen in this cohort of inpatients in a quarternary cancer centre. Future research should focus on pain type and aetiology, and pain scores in different cancer pain syndromes to determine the net effect of opioids and adjuvants in cancer pain prescribing.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	AME Publishing Company
dc.relation.ispartof	Ann Palliat Med
dc.relation.isbasedon	10.21037/apm-22-1296
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	4203 Health services and systems
dc.subject.mesh	Humans
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Cancer Pain
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Analgesics
dc.subject.mesh	Pain
dc.subject.mesh	Neoplasms
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Pain
dc.subject.mesh	Analgesics
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Cancer Pain
dc.subject.mesh	Humans
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Cancer Pain
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Analgesics
dc.subject.mesh	Pain
dc.subject.mesh	Neoplasms
dc.title	Does cancer type and adjuvant analgesic prescribing influence opioid dose?-a retrospective cross-sectional study.
dc.type	Journal Article
utslib.citation.volume	12
utslib.location.activity	China
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
dc.date.updated	2023-11-07T04:28:49Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	12
utslib.citation.issue	4

Abstract:

Opioids are the backbone of cancer pain management. Minimal evidence exists examining the relationship between cancer type and opioid dose. Similarly, the use of adjuvant analgesics and its impact within an inpatient cancer setting is understudied. This study examined the influence of cancer type upon opioid dose, measured by oral morphine equivalent daily dose (oMEDD). The effect of adjuvant analgesics on patient oMEDD was also examined. This retrospective cross-sectional study examined records of 520 patients admitted to Royal Melbourne Hospital or Peter MacCallum Cancer Centre between 2016 and 2018 with advanced cancer. Number and dose of both opioid and adjuvant analgesics were collected along with demographic and cancer data. Comparisons of median oMEDD by cancer type [analysis of variance (ANOVA), non-parametric t-tests] and adjuvant analgesics (Kruskal-Wallis test) were performed. There were no statistically significant differences in oMEDD between the 12 cancer types (P=0.83; n=215). Patients co-prescribed pregabalin (n=102) and paracetamol (n=73) as adjuvant analgesics were on significantly higher daily oMEDD [60 mg (P=0.015), 90 mg (P<0.001), respectively]. Opioid dose did not differ significantly between cancer types. The observed use of adjuvant analgesics coincided with significantly higher oMEDD prescription which may relate to complex pain seen in this cohort of inpatients in a quarternary cancer centre. Future research should focus on pain type and aetiology, and pain scores in different cancer pain syndromes to determine the net effect of opioids and adjuvants in cancer pain prescribing.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/173196